O-2113

Summary

O-2113 is a drug that is a classical cannabinoid derivative,[1] which acts as a potent agonist for cannabinoid receptors, producing sedation, hypothermia and analgesia in animal studies.[2]

O-2113
Identifiers
  • (6aR,10aR)-3-(1-Ethanesulfonylamino-5-methyl-hexan-5-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
PubChem CID
  • 11775273
ChemSpider
  • 26333261
Chemical and physical data
FormulaC25H39NO4S
Molar mass449.65 g·mol−1
3D model (JSmol)
  • Interactive image
  • C13CC=C(C)CC3c2c(OC1(C)C)cc(C(C)(C)CCCCNS(=O)(=O)CC)cc2O
  • InChI=1S/C25H39NO4S/c1-7-31(28,29)26-13-9-8-12-24(3,4)18-15-21(27)23-19-14-17(2)10-11-20(19)25(5,6)30-22(23)16-18/h10,15-16,19-20,26-27H,7-9,11-14H2,1-6H3/t19-,20-/m1/s1
  • Key:UMJJTCXPFDHKGJ-WOJBJXKFSA-N
 ☒NcheckY (what is this?)

See also edit

References edit

  1. ^ Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, et al. (January 2011). "Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist". European Journal of Pharmacology. 651 (1–3): 96–105. doi:10.1016/j.ejphar.2010.10.085. PMC 3034309. PMID 21114999.
  2. ^ US 7279500, Martin BR, Razdan RJ, Pertwee RG, "Sulfonamide Cannabinoid Agonists and Antagonists", published 5 May 2005